DDInter948 DDInter1105
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lurbinectedin {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lurbinectedin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lurbinectedin may lead to a major life threatening interaction when taken with Ribociclib
Lurbinectedin may lead to a major life threatening interaction when taken with Upadacitinib